Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-escalation and Phase IIa Study of TG6002 Plus Flucytosine in Patients With Unresectable Colorectal Cancer With Liver Metastases

NCT04194034 is registered in ClinicalTrials.gov with Transgene as lead sponsor.

NCT NCT04194034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04194034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-escalation and Phase IIa Study of TG6002 Plus Flucytosine in Patients With Unresectable Colorectal Cancer With Liver Metastases
Lead sponsor
Transgene
Phase
Phase 1/2
Overall status
Terminated
Start date
January 17, 2020
Completion date
February 23, 2023
Enrollment
15 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms